1354701-20-4

Basic information

• Product Name: (9Z,12Z)-1-(2-(3,4-dihydroxyphenyl)ethoxy)-octadeca-9,12-diene
• CAS NO: 1354701-20-4
• Molecular Weight: 402.618
• Mol File: 1354701-20-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (9Z,12Z)-1-(2-(3,4-dihydroxyphenyl)ethoxy)-octadeca-9,12-diene(CAS DataBase Reference)
• NIST Chemistry Reference: (9Z,12Z)-1-(2-(3,4-dihydroxyphenyl)ethoxy)-octadeca-9,12-diene(1354701-20-4)
• EPA Substance Registry System: (9Z,12Z)-1-(2-(3,4-dihydroxyphenyl)ethoxy)-octadeca-9,12-diene(1354701-20-4)

Safety Data

• Hazardous Substances Data: 1354701-20-4(Hazardous Substances Data)

Upstream product

• 1354701-25-9 (9Z,12Z)-1-(2-(3,4-(dimethylmethylenedioxy)phenyl)ethoxy)octadeca-9,12-diene 
• 119054-91-0 2-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethan-1-ol 
• 60839-74-9 (6Z,9Z)-18-bromooctadeca-6,9-diene 

Relevant articles and documents

HYDROXYTYROSOL ETHERS

The invention relates to hydroxytyrosol ethers derived from fatty alcohols and phenolic compounds of olive oil and the salts, solvates and hydrates thereof, which have an affinity for type 1 cannabinoid receptors (CB1) and which can: prevent the oxidation of low-density lipoprotein (LDL); and modulate the actions regulated by said receptor, such as inducing satiety, controlling intake and reducing body fat.

Unsaturated fatty alcohol derivatives of olive oil phenolic compounds with potential low-density lipoprotein (LDL) antioxidant and antiobesity properties

A new route for the synthesis of fatty alcohol derivatives of hydroxytyrosol and other olive oil phenolic compounds was developed to allow the preparation of unsaturated derivatives. The biological activity of synthesized compounds was evaluated. Most of the compounds presented a significant antioxidant activity on low-density lipoprotein (LDL) particles. The activity of the tested products was significantly influenced by the number and position of unsaturations as well as modifications on the polar head of the synthesized compounds. Some of them presented modulation of food intake in rats and, due to their molecular similarity with CB1 endogenous ligands, the endocannabinoid system and PPAR-α were also evaluated as potential targets. The pharmacodynamics could not be totally explained by CB1 and PPAR-α receptor interactions because only two of the four compounds with biological activity showed a CB1 activity and all of them presented low PPAR-α affinity, not justifying its whole in vivo activity. The hydroxytyrosol linoleylether (7) increased LDL resistance to oxidation with a capacity similar to that of hydroxytyrosol and was the most active in vivo compound with a hypophagic effect comparable to that of oleoylethanolamine. We consider that this compound could be a good lead compound for future drug development in obesity treatments.